Daan Gene Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangzhou Daan Gene Co., Ltd. (hereinafter referred to as "Daan Gene" or "Company") is a state-owned biopharmaceutical high-tech enterprise led by molecular diagnostic technology, integrating independent research and development, production, and sales of clinical laboratory reagents, instruments, and supporting consumables. As one of the first batch of in vitro diagnostic high-tech enterprises in China, the company was listed on the Shenzhen Stock Exchange in 2004 (stock code: SZ002030). Daan Gene focuses on the research and application of fluorescent PCR diagnostic reagent products. It is not only the pioneer of China's nucleic acid testing technology, but also an important contributor to China's nucleic acid testing technology products becoming representative of the international cutting-edge technology level. The company has undertaken 38 national and provincial key research projects, and its research achievements have successively won various awards such as the China Patent Gold Award and the National Science and Technology Progress Award. After thirty years of accumulation, Daan Gene PCR technology has been integrated into the entire industry chain, including research and development and production, core raw materials, quality control products, instrument research and development and production, and testing services. As a trusted unit of research centers such as the Medical Biotechnology Research Center of the Ministry of Health, the National Clinical Molecular Diagnosis National and Local Joint Engineering Laboratory, the Guangzhou Molecular Diagnosis Technology Research Center, the National Certified Enterprise Technology Center, and the Guangzhou Antibody Technology Research Center, Daan Gene has been selected as a national intellectual property demonstration enterprise, The independently developed product has been awarded titles such as "National Key New Product" and "Guangdong Province Key New Product". As of now, the company has applied for a total of 517 invention patents, including 102 authorized invention patents, covering various aspects such as prenatal screening, newborn screening, hormone testing, pathological diagnosis, public health monitoring, real-time diagnosis of infectious diseases, tumor gene mutation detection, personalized medication guidance, etc. As a leading enterprise in molecular diagnosis, Daan Gene has played a huge role in the prevention and control of new and sudden infectious diseases. During the anti epidemic period, the novel coronavirus 2019 nCOV nucleic acid detection kit (fluorescent PCR method) independently developed and produced by Daan Gene was the first batch of COVID-19 nucleic acid detection reagents released and developed in China. It was the first CE certificate in the world and included in the World Health Organization (WHO) emergency use list. The anti epidemic products produced by the company have reached over 140 countries and regions. |
| Headquarter | Guangzhou |
| Establish Date | 8/17/1988 |
| Listed Code | 002030.SZ |
| Listed Date | 8/9/2004 |
| Chairman | Xue Zheqiang. |
| CEO | Huang Luo. |
| Website | www.daangene.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
